Valion Bio (VBIO)
NASDAQ:VBIO
Want to see VBIO full AI Analyst Report?
Top Page
Valion Bio
(NASDAQ:VBIO)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.89
▼(-35.36% Downside)
Action:ReiteratedDate:05/02/26
The score is primarily constrained by very weak financial performance (shrinking revenue, persistent losses, negative cash flow, and significant balance-sheet erosion). Technicals are mixed but generally pressured by longer-term downtrends, while valuation is hard to support due to negative earnings and no dividend data.
Positive Factors
Low Leverage
Reported zero debt in 2024–2025 materially reduces bankruptcy and interest-service risk, preserving balance-sheet flexibility. Over a 2–6 month horizon this low leverage supports survival through weak operations and provides optionality to raise structured financing or equity on more favorable terms if needed.
Negative Factors
Declining Revenue
A multi-year revenue decline signifies weakening demand and loss of scale, which undermines gross margin recovery and operating leverage. Over 2–6 months this constrains resource allocation for marketing, R&D, and distribution, making it harder to rebuild market position without material new investment or a strategic commercial shift.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Reported zero debt in 2024–2025 materially reduces bankruptcy and interest-service risk, preserving balance-sheet flexibility. Over a 2–6 month horizon this low leverage supports survival through weak operations and provides optionality to raise structured financing or equity on more favorable terms if needed.
Read all positive factors
Valion Bio (VBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.01M
Dividend YieldN/A
Average Volume (3M)99.84K
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue Growth-49.63%
EPS Growth82.22%
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding2,877,926
10 Day Avg. Volume91,463
30 Day Avg. Volume99,839
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)17.36
Price to Sales (P/S)197.61
P/FCF Ratio-41.06
Enterprise Value/Market Cap6.92
Enterprise Value/Revenue26.73
Enterprise Value/Gross Profit-108.59
Enterprise Value/Ebitda-36.49
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Valion Bio Business Overview & Revenue Model
Company Description
Vitality Biopharma, Inc. engages in the development of cannabinoid pharmaceuticals for the treatment of inflammatory disorders in the United States. The company is developing tetrahydrocannabinol glycoside (VBX-100), an oral cannabinoid prodrug fo...
How the Company Makes Money
Tivic Health Systems primarily makes money by selling its ClearUP device and related accessories to customers, with revenue recognized from product sales through direct-to-consumer channels and/or retail or distribution partners. To the extent the...
Valion Bio Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
25
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Mar 2022 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 778.77K | 0.00 | 0.00 | 0.00 | 102.42K | 163.36K |
| Gross Profit | -191.73K | 0.00 | 0.00 | 0.00 | 24.48K | 55.10K |
| EBITDA | -570.55K | -880.85K | -4.37M | -4.43M | -4.31M | -5.22M |
| Net Income | -633.38K | -880.85K | -4.37M | -20.14M | -4.31M | -5.22M |
Balance Sheet | ||||||
| Total Assets | 56.75M | 896.83K | 2.57M | 6.08M | 675.79K | 1.18M |
| Cash, Cash Equivalents and Short-Term Investments | 285.39K | 884.14K | 2.39M | 5.98M | 656.29K | 1.15M |
| Total Debt | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 49.04M | 33.44K | 1.28M | 1.05M | 353.52K | 800.65K |
| Stockholders Equity | 5.82M | 863.39K | 1.28M | 5.02M | 322.27K | 374.37K |
Cash Flow | ||||||
| Free Cash Flow | 964.82K | -1.61M | -3.59M | -3.67M | -2.89M | -1.38M |
| Operating Cash Flow | 964.82K | -1.61M | -3.59M | -3.67M | -2.89M | -1.38M |
| Investing Cash Flow | -328.87K | 0.00 | 0.00 | 141.54K | 0.00 | 0.00 |
| Financing Cash Flow | 308.86K | 96.99K | 0.00 | 8.85M | 2.39M | 2.44M |
Valion Bio Technical Analysis
Positive
1.38
Price Trends
0.91
Positive
1.26
Positive
2.19
Negative
Market Momentum
0.04
Negative
67.56
Neutral
91.06
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VBIO, the sentiment is Positive. The current price of 1.38 is above the 20-day moving average (MA) of 0.99, above the 50-day MA of 0.91, and below the 200-day MA of 2.19, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 67.56 is Neutral, neither overbought nor oversold. The STOCH value of 91.06 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VBIO.
Valion Bio Risk Analysis
Valion Bio disclosed 48 risk factors in its most recent earnings report. Valion Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Valion Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $25.96M | -120.91 | 9999.00% | ― | -44.57% | 55.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $3.77M | -0.28 | -191.39% | ― | ― | 64.06% | |
44 Neutral | $3.01M | -0.05 | -202.20% | ― | -49.63% | 82.22% | |
44 Neutral | $1.83M | -0.21 | -145.52% | ― | ― | 99.07% | |
41 Neutral | $2.76M | -0.29 | -6046.59% | ― | -5.38% | 94.40% |
* Healthcare Sector Average
VBIO
Valion Bio
1.05
-3.32
-76.03%
NUWE
Nuwellis
1.12
-38.38
-97.16%
AEMD
Aethlon Medical
2.40
-28.24
-92.17%
BBLG
Bone Biologics
1.34
-2.68
-66.67%
MOVE
Movano
13.10
6.40
95.49%
BJDX
Bluejay Diagnostics
1.89
-5.16
-73.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.